Literature DB >> 10786666

Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.

M G Narducci1, E Pescarmona, C Lazzeri, S Signoretti, A M Lavinia, D Remotti, E Scala, C D Baroni, A Stoppacciaro, C M Croce, G Russo.   

Abstract

Chromosomal rearrangements observed in T-cell prolymphocytic leukemia involve the translocation of one T-cell receptor gene to either chromosome 14q32 or Xq28, deregulating the expression of cellular protooncogenes of unknown function, such as TCL1 or its homologue, MTCP1. In the human hematopoietic system, TCL1 expression is predominantly observed in developing B lymphocytes, whereas its overexpression in T cells causes mature T-cell proliferation in transgenic mice. In this study, using a newly generated monoclonal antibody against recombinant TCL1 protein, we extended our analysis mainly by immunohistochemistry and also by fluorescence-activated cell sorting and Western blot to a large tumor lymphoma data bank including 194 cases of lymphoproliferative disorders of B- and T-cell origin as well as reactive lymphoid tissues. The results obtained show that in reactive lymphoid tissues, TCL1 is strongly expressed by a subset of mantle zone B lymphocytes and is expressed to a lesser extent by follicle center cells and by scattered interfollicular small lymphocytes. In B-cell neoplasia, TCL1 was expressed in the majority of the cases, including lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (60%), and primary cutaneous B cell lymphoma (55%). TCL1 expression was observed in both the cytoplasmic and nuclear compartments, as confirmed by Western blot analysis. Conversely, TCL1 was not expressed in Hodgkin/Reed-Sternberg cells, multiple myelomas, marginal zone B-cell lymphomas, CD30+ anaplastic large cell lymphoma, lymphoblastic T-cell lymphoma, peripheral T-cell lymphoma, and mycosis fungoides. These data indicate that TCL1 is expressed in more differentiated B cells, under both reactive and neoplastic conditions, from antigen committed B cells and in germinal center B cells and is down-regulated in the latest stage of B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786666

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

2.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Authors:  Jinsheng Weng; Seema Rawal; Fuliang Chu; Hyun Jun Park; Rakesh Sharma; David A Delgado; Luis Fayad; Michelle Fanale; Jorge Romaguera; Amber Luong; Larry W Kwak; Sattva S Neelapu
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

3.  MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Authors:  Luciano Mazzoccoli; Marcela Cristina Robaina; Alexandre Gustavo Apa; Martin Bonamino; Luciana Wernersbach Pinto; Eduardo Queiroga; Carlos E Bacchi; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-09       Impact factor: 4.553

4.  AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.

Authors:  Tasneem Motiwala; Nicola Zanesi; Jharna Datta; Satavisha Roy; Huban Kutay; Allyn M Checovich; Mohamed Kaou; Yiming Zhong; Amy J Johnson; David M Lucas; Nyla A Heerema; John Hagan; Xiaokui Mo; David Jarjoura; John C Byrd; Carlo M Croce; Samson T Jacob
Journal:  Blood       Date:  2011-10-14       Impact factor: 22.113

5.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

6.  Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.

Authors:  Rhine R Shen; David O Ferguson; Mathilde Renard; Katrina K Hoyer; Unkyu Kim; Xingpei Hao; Frederick W Alt; Robert G Roeder; Herbert C Morse; Michael A Teitell
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

7.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

8.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

9.  The TCL1 function revisited focusing on metabolic requirements of stemness.

Authors:  Maria Teresa Fiorenza; Alessandro Rava
Journal:  Cell Cycle       Date:  2019-09-29       Impact factor: 4.534

Review 10.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.